

Prof. DR. MED. MARTIN SPAHN

Publications

I ORIGINAL ARTICLE

Number: 62 (11 First-/ 5 Seniorauthor)
 Cumulative IF: 329.9
 Citation: 1668
 Hirsch-Index: 23

Nr.	Author / Titel / Year	*IF	*Citation
1	Zoni E, Minoli M, Bovet C, Wehrhan A, Piscuoglio S, Ng CKY, Gray PC, Spahn M , Thalmann GN, Kruithof-de Julio M. Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification. BMC Cancer. 2019 Dec 16;19(1):1216	2.933	
2	Krebs M, Behrmann C, Kalogirou C, Sokolakis I, Kneitz S, Kruithof-de Julio M, Zoni E, Rech A, Schilling B, Kübler H, Spahn M , Kneitz B. miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1. Biomed Res Int. 2019 Nov 14;2019:6392748	2.197	
3	Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M , Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol Oncol. 2019 Jul;2(4):456-463	n.a.	1
4	Kiener M, Chen L, Krebs M, Grosjean J, Klima I, Kalogirou C, Riedmiller H, Kneitz B, Thalmann GN, Snaar-Jagalska E, Spahn M , Kruithof-de Julio M, Zoni E. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo. BMC Cancer. 2019 Jun 25;19(1):627	2.933	
5	González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M , Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G. Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. Eur J Surg Oncol. 2019 Oct;45(10):1983-1992	3.379	
6	Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H,	n.a.	0

	Tombal B, Spahn M, Joniau S, Montorsi F, Briganti A, on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. <i>European Urology Oncology</i> , in press.		
7	Gössi F, Spahn M , Samaras P, Beyer J, Schardt J, Pabst T <u>Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients.</u> <i>Bone Marrow Transplant</i> . 2018 Jan 24. doi: 10.1038/s41409-018-0089-5.	4.497	0
8	Astrologo L, Zoni E, Karkampouna S, Gray PC, Klima I, Grosjean J, Goumans MJ, Hawinkels LJAC, van der Pluijm G, Spahn M, Thalmann GN, Ten Dijke P, Kruithof-de Julio M. <u>ALK1Fc Suppresses the Human Prostate Cancer Growth in <i>in Vitro</i> and <i>in Vivo</i> Preclinical Models.</u> <i>Front Cell Dev Biol</i> . 2017 Dec 5;5:104.	n.a.	0
9	Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M , Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urol Oncol</i> . 2018 Feb;36(2):79.e11-79.e17.	3.397	3
10	Lacombe D, Coens C, de Balincourt C, Licitra L, den Dulk M, Machiels JP, Weber D, Spahn M , Salgado R, Kasper B, Hau P, Betsou F, Kataoka K, Caballero C, Liu Y, Hurkmans C, Evrard S. Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC). <i>Eur J Cancer</i> . 2017 Sep 28;86:91-100. doi: 10.1016	7.191	8
11	Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M , Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>Eur Urol Focus</i> . 2017 Jan 17. pii: S2405-4569(17)30002-0. doi: 10.1016/j.euf.2016.12.008.	n.a.	5
12	Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M , Joniau S. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. <i>Prostate Cancer Prostatic Dis</i> . 2017 May 9. In press	4.099	4
13	Spahn M , Morlacco A, Boxler S, Joniau S, Briganti A, Montorsi F, Gontero P, Kneitz B, Bader P, Frohneberg D, van Poppel H,	4.688	3

	Karnes RJ, on behalf of the “European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients. <i>BJU Int.</i> 2017 Nov;120(5B):E52-E58. doi: 10.1111/bju		
14	Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M , Briganti A, Joniau S. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Front Surg.</i> 2016 Dec 16;3:65. doi: 10.3389/fsurg.2016.00065.	n.a.	7
15	Gössi F, Spahn M , Zweifel M, Panagiotis S, Mischo A, Stenner F, Hess U, Berthold D, Bargetzi M, Schardt J, Pabst T. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. <i>Bone Marrow Transplant.</i> 2016 Nov 28. doi: 10.1038/bmt.2016.285.	4.497	1
16	Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium., Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M , Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. <i>J Surg Oncol.</i> 2016 Nov;114(6):764-768.	2.886	13
17	Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V, Larré S, di Stasi S, Colombo R, Babjuk M, Malmström PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M , Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urol Oncol.</i> 2016 Nov;34(11):484.e19-484.e25.	3.397	23
18	Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M , Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. <i>World J Urol.</i> 2016 Feb 20.	2.981	3
19	Dell'Oglio P, Karnes RJ, Joniau S, Spahn M , Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urol Oncol.</i> 2015 Dec 16. pii: S1078-1439(15)00570-0. doi: 10.1016/j.urolonc.2015.11.018.	3.397	7

20	Nguyen, H. G., D. Tilki, M. A. Dall'Era, B. Durbin-Johnson, J. A. Carballido, T. Chandrasekar, T. Chromecki, G. Ciancio, S. Daneshmand, P. Gontero, J. Gonzalez, A. Haferkamp, M. Hohenfellner, W. C. Huang, E. Linares Espinos, P. Mandel, J. I. Martinez-Salamanca, V. A. Master, J. M. McKiernan, F. Montorsi, G. Novara, S. Pahernik, J. Palou, R. S. Pruthi, O. Rodriguez-Faba, P. Russo, D. S. Scherr, S. F. Shariat, M. Spahn , C. Terrone, D. Vergho, E. M. Wallen, E. Xylinas, R. Zigeuner, J. A. Libertino and C. P. Evans (2015). "Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis." J Urol. 2015 Aug;194(2):304-8	5.381	11
21	Litovkin, K., A. Van Eynde, S. Joniau, E. Lerut, A. Laenen, T. Gevaert, O. Gevaert, M. Spahn , B. Kneitz, P. Gramme, T. Helleputte, S. Isebaert, K. Haustermans and M. Bollen (2015). "DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer." PLoS One. 2015 Jun 18;10(6):e0130651.	2.766	14
22	Briganti, A., R. J. Karnes, G. Gandaglia, M. Spahn , P. Gontero, L. Tosco, B. Kneitz, F. K. H. Chun, E. Zaffuto, M. Sun, M. Graefen, G. Marchioro, D. Frohneberg, S. Giona, P. I. Karakiewicz, H. Van Poppel, F. Montorsi, S. Joniau, C. European Multicenter Prostate Cancer, R. Translational and Group (2015). "Natural history of surgically treated high-risk prostate cancer." Urol Oncol. 2015 Apr;33(4):163.e7-13	3.397	30
23	Moltzahn, F., J. Karnes, P. Gontero, B. Kneitz, B. Tombal, P. Bader, A. Briganti, F. Montorsi, H. Van Poppel, S. Joniau and M. Spahn (2015). "Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients." Prostate Cancer Prostatic Dis. 2015 Mar;18(1):31-7.	4.099	15
24	Tilki, D., B. Hu, H. G. Nguyen, M. A. Dall'Era, R. Bertini, J. A. Carballido, T. Chandrasekar, T. Chromecki, G. Ciancio, S. Daneshmand, P. Gontero, J. Gonzalez, A. Haferkamp, M. Hohenfellner, W. C. Huang, T. M. Koppie, E. Linares, C. A. Lorentz, P. Mandel, J. I. Martinez-Salamanca, V. A. Master, R. Matloob, J. M. McKiernan, C. M. Mlynarczyk, F. Montorsi, G. Novara, S. Pahernik, J. Palou, R. S. Pruthi, K. Ramaswamy, O. Rodriguez Faba, P. Russo, S. F. Shariat, M. Spahn , C. Terrone, W. Thieu, D. Vergho, E. M. Wallen, E. Xylinas, R. Zigeuner, J. A. Libertino and C. P. Evans (2015). "Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy." J Urol. 2015 Feb;193(2):436-42.	5.381	14
25	* Joniau, S. , * M. Spahn , A. Briganti, G. Gandaglia, B. Tombal, L. Tosco, G. Marchioro, C.-Y. Hsu, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, R. J. Karnes, F. Montorsi, H. van Poppel, P. Gontero and C. European Multicenter Prostate (2015). "Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer." Eur Urol. 2015 Feb;67(2):319-25.* joint first author	17.581	9

26	Gontero, P., R. Sylvester, F. Pisano, S. Joniau, K. V. Eeckt, V. Serretta, S. Larre, S. Di Stasi, B. Van Rhijn, A. J. Witjes, A. J. Grotenhuis, L. A. Kiemeney, R. Colombo, A. Briganti, M. Babjuk, P.-U. Malmstrom, M. Oderda, J. Irani, N. Malats, J. Baniel, R. Mano, T. Cai, E. K. Cha, P. Ardelt, J. Varkarakis, R. Bartoletti, M. Spahn , R. Johansson, B. Freja, V. Soukup, E. Xylinas, G. Dalbagni, R. J. Karnes, S. F. Shariat and J. Palou (2015). "Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients." <i>Eur Urol.</i> 2015 Jan;67(1):74-82.	17.581	81
27	Joniau, S., A. Briganti, P. Gontero, G. Gandaglia, L. Tosco, S. Fieuws, B. Tombal, G. Marchioro, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, R. J. Karnes, F. Montorsi, H. Van Poppel and M. Spahn . <i>European Multictr Prostate Canc</i> (2015). "Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study." <i>Eur Urol.</i> 2015 Jan;67(1):157-64	17.581	97
28	Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M , Kneitz B, Isebaert S, Haustermans K, Beullens M, Van Eynde A, Bollen M. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. <i>J Cancer Res Clin Oncol.</i> Nov. 2014, Vol. 140, 1849-61.	3.282	20
29	Vergo D, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, Spahn M , Löser A, Kocot A, Riedmiller H, Kneitz B. Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. <i>PLoS One</i> , 2014 Oct 3;9(10):e109877. doi:10.1371/journal.pone.0109877. eCollection 2014	2.766	22
30	Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M , Terrone C, Vergo D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>Eur Urol.</i> 2014 Sep;66(3):577-83	17.581	40
31	Hailer, A., T. G. P. Grunewald, M. Orth, C. Reiss, B. Kneitz, M. Spahn and E. Butt (2014). "Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration." <i>Oncotarget.</i> 2014 Jun 30;5(12):4144-4153	n.a.	51
32	Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Ströbel P, Gessler M, Riedmiller H, Spahn M . Survival in high-risk prostate cancer patients is predicted by mir-221, which regulates proliferation, apoptosis and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. <i>Cancer Res.</i> 2014 May 1;74(9):2591-603.	9.13	76
33	Vergo D, Kneitz S, Rosenwald A, Scherer C, Spahn M , Burger M, Riedmiller H, Kneitz B. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival	3.288	33

	in clear-cell renal cell carcinoma. BMC Cancer. 2014 Jan 15;14:25.		
34	Kalogirou C, Spahn M , Krebs M, Joniau S, Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H, Kneitz B. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci. 2013 Oct 29;14(11):21414-34.	3.687	31
35	Loeser, A., M. Neumann, A. Kocot, D. C. Vergho, M. Spahn and H. Riedmiller (2013). "Serum carcino-embryonic antigen (CEA) and its possible use as tumor marker for secondary tumors in urinary intestinal reservoirs." Urol Oncol. 2013 Jul;31(5):644-8.	3.397	5
36	Schubert M, Spahn M , Kneitz S, Scholz CJ, Joniau S, Stroebe P, Riedmiller H, Kneitz B. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One. 2013 Jun 14;8(6):e65064	2.766	54
37	Briganti A, Spahn M , Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. Eur Urol. 2013 Apr;63(4):693-701	17.581	68
38	Belharazem D, Kirchner M, Geissler F, Bugert P, Spahn M , Kneitz B, Riedmiller H, Sauer C, Küffer S, Trojan L, Bolenz C, Michel MS, Marx A, Ströbel P. Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer. Endocr Connect. 2012 Oct 24;1(2):87-94	n.a.	5
39	Spahn M , Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. J Urol. 2012 Jul;188(1):84-90.	5.381	21
40	Joniau S, Hsu CY, Gontero P, Spahn M , Van Poppel H. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol. 2012 Jun;46(3):164-71.	1.684	22
41	Kälble T, Hofmann I, Thüroff JW, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truß M, Roth S, von Rundstedt FC, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M , Bader P, Steffens J, Harzmann R, Stief CG, Karl A, Müller SC, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübber H, Juenemann KP, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon WF, Miller S, Weingärtner K, Schilling A, Piechota H, Becht JE, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M. Secondary malignancies in urinary diversions. Urologe A. 2012 Apr;51(4):500, 502-6	0.437	5
42	Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D,	17.581	86

	Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M . Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. <i>Eur Urol.</i> 2012 Mar;61(3):584-92		
43	Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M . The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. <i>Adv Urol.</i> 2012;2012:612707.	n.a.	0
44	Vergho, D. C., A. Loeser, A. Kocot, M. Spahn and H. Riedmiller (2012). "Tumor thrombus of inferior vena cava in patients with renal cell carcinoma - clinical and oncological outcome of 50 patients after surgery." <i>BMC research notes</i> 5: 5-5	n.a.	5
45	Gontero P, Spahn M , Tombal B, Bader P, Hsu CY, Marchioro G, Frea B, Van Der Eeckt K, Kneitz B, Frohneberg D, Tizzani A, Van Poppel H, Joniau S. Is there a prostate-specific antigen upper limit for radical prostatectomy? <i>BJU Int.</i> 2011 Oct;108(7):1093-100.	4.688	18
46	Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, Kroiss M, Jurowich C, Langer P, Oelkers W, Spahn M , Willenberg HS, Mäder U, Allolio B, Fassnacht M. Deficits in the management of patients with adrenocortical carcinoma in Germany. <i>Dtsch Arztebl Int.</i> 2010 Dec;107(50):885-91	3.89	38
47	Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M , Hahner S, Allolio B; German ACC Registry Group. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. <i>J Clin Endocrinol Metab.</i> 2010 Nov;95(11):4925-32.	5.789	88
48	Kocot A, Spahn M , Loeser A, Lopau K, Gerharz EW, Riedmiller H. Long-term results of a staged approach: continent urinary diversion in preparation for renal transplantation. <i>J Urol.</i> 2010 Nov;184(5):2038-42.	5.381	7
49	Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M , Weismann D, Hahner S, Fassnacht M; German Adrenocortical Carcinoma Registry Group. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. <i>Eur Urol.</i> 2010 Oct;58(4):609-15.	17.581	161
50	Reiss C, Haneke T, Völker HU, Spahn M , Rosenwald A, Edelmann W, Kneitz B. Conditional inactivation of MLH1 in thymic and naive T-cells in mice leads to a limited incidence of lymphoblastic T-cell lymphomas. <i>Leuk Lymphoma.</i> 2010 Oct;51(10):1875-86.	2.644	9
51	Spahn M , Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. <i>Int J Cancer.</i> 2010 Jul 15;127(2):394-403.	7.36	150
52	Spahn M , Joniau S, P, Fieuws S, Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P, Frohneberg D, Tizzani A, Van Poppel H. Outcome predictors of radical prostatectomy in	17.581	107

	patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1		
53	Spahn M , Kocot A, Loeser A, Kneitz B, Riedmiller H. Last resort in devastated bladder outlet: bladder neck closure and continent vesicostomy--long-term results and comparison of different techniques. Urology. 2010 May;75(5):1185-92.	2.3	20
54	Spahn M , Weiss C, Bader P, Frohneberg D, Studer UE, Burkhard FC. The role of exenterative surgery and urinary diversion in persistent or locally recurrent gynecological malignancy: complications and survival. Urol Int. 2010;85(1):16-22.	1.508	6
55	Spahn M , Weiss C, Bader P, Ströbel P, Gerharz EW, Kneitz B, Frohneberg D. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int. 2010;84(2):164-73.	1.508	30
56	Loeser A, Vergho DC, Katzenberger T, Brix D, Kocot A, Spahn M , Gerharz EW, Riedmiller H. Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors. Urology. 2009 Aug;74(2):370-2	2.3	26
57	Lehmann J, Suttman H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M , Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol. 2009 Jun;55(6):1293-9.	17.581	76
58	Lehmann J, Suttman H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M , Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Complete resection of urothelial cancer metastases with curative intent. Urologe A. 2009 Feb;48(2):143-50.	0.437	2
59	Spahn M , Vergho D, Riedmiller H. Iatrogenic recto-urethral fistula: perineal repair and buccal mucosa interposition. BJU Int. 2009 Jan;103(2):242-6.	4.688	18
60	Knoll T, Michel MS, Cueva-Martínez A, Spahn M , Bross S, Alken P, Köhrmann KU. Evaluation of superficial papillary ablation by endoscopic lasers in an ex vivo kidney model. J Endourol. 2002 Apr;16(3):195-200.	2.038	3
61	Spahn M , Portillo FJ, Michel MS, Siegsmond M, Gaa J, Alken P, Jünemann KP. Color Duplex sonography vs. computed tomography: accuracy in the preoperative evaluation of renal cell carcinoma. Eur Urol. 2001 Sep;40(3):337-42.	17.581	10
62	Krautschick A, Spahn M , Christman S, Michel MS, Alken P.: Experimentell induzierte Deposition von Kalzium-Oxalat-Kristallen in der Kaninchenniere und Bedeutung für die humane Lithiasis. Aktuelle Urologie,30, 1999; 35-40	0.235	0

Liegt noch nicht vor

* Impactfaktoren gemäss Journal Citation report des Institute for Scientific Information (2018)

** Zitationen gemäss Institute for Scientific Information (13.01.2020)

II CASE REPORTS

Number: 5 (1 First Author)
 Cumulative IF: 4.3
 Citation: 5

Nr.	Author / Titel / Year	*IF	*Citation
1	Kocot A, Spahn M , Loeser A, Riedmiller H. Recto-vesico-cutaneous fistula following salvage cryotherapy of the prostate due to recurrent localized prostate cancer]. Urologe A. 2011 Nov;50(11):1428-30.	0.437	1
2	Loeser A, Kocot A, Spahn M , Riedmiller H. Urethro-crural fistula to the adductor canal. Late complication following radiotherapy for recurrent prostate cancer]. Urologe A. 2011 Nov;50(11):1438-40.	0.437	0
3	Letsch M, Spahn M , Beissert M, Topp MS, Gerharz EW, Riedmiller H. The worst case: giant exulcerating seminoma. Urol Int. 2010;84(1):113-5.	1.508	1
4	Loeser A, Katzenberger T, Spahn M , Gerharz EW, Riedmiller H. Metanephric adenoma in a two-year-old child. Urol Int. 2009;83(1):119-21.	1.508	1
5	Spahn M , Portillo FJ, Grobholz R, Jünemann KP, Alken P. Fibromyxoid pseudosarcoma of the urinary bladder. Case report and review of the literature of a rare disease]. Urologe A. 2001 Jul;40(4):315-8.	0.437	2

* Impactfaktoren gemäss Journal Citation report des Institute for Scientific Information (2018)

** Zitationen gemäss Institute for Scientific Information (13.01.2020)

III REVIEW ARTICLE

Number: 24 (9 First-/Seniorauthor)
 Cumulative IF: 72.6
 Citation: 278

Nr.	Author / Titel / Year	*IF	*Citation
1*	Omlin A, Spahn M , Beyer J, Eberli D, Gillissen S, Jochum W, Kueng M, Nitzsche E, Rentsch CA, Roggero E, Schmid HP, Stenner F, Templeton AJ, Wild D, Wyler S, Zwahlen D, Cathomas R. Treatment of Advanced Prostate Carcinoma-an interdisciplinary Recommendation. Praxis (Bern 1994). 2018 Sep;107(19):1043-1051	n.a.	0
2*	Zoni, E., Karkampouna, S., Thalmann, G. N., Kruihof-de Julio, M. and Spahn, M . Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy Mol Cell Endocrinol. 2017 Feb 9. pii: S0303-7207(17)30089-8. doi: 10.1016/j.mce.2017.02.009.	3.563	2
3*	Moltzahn F, Dal Pra A, Furrer M, Thalmann G, Spahn M . <u>Urethral strictures after radiation therapy for prostate cancer</u> . Investigative and clinical urology Volume: 57 Issue: 5 Pages: 309-315 Published: SEP 2016	n.a.	4
4*	Moschini M, Spahn M , Mattei A, Cheville J, Karnes RJ. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med. 2016 Apr Moschini M, BMC Med. 2016 Apr 4;14(1):67. doi: 10.1186/s12916-016-0613-7.	9.088	31

5*	Rozet F, Roumeguère T, Spahn M , Beyersdorff D, Hammerer P. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. <i>World J Urol.</i> 2016 Nov;34(11):1505-1513.	2.981	7
6*	Spahn M und Boxler S. Harnableitung beim älteren Patienten. <i>Der Urologe</i> 2015 Dec;54(12):1753-7	0.437	0
7*	Spahn M , Boxler S, Joniau S, Moschini M, Tombal B and Karnes RJ. What is the Need for Prostatic Biomarkers in Prostate Cancer Management? <i>Curr Urol Rep.</i> 2015 Oct;16(10):70. doi: 10.1007/s11934-015-0545-3.	1.983	6
8*	Martinez-Salamanca JI, Linares E, Gonzalez J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M , Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Current Urology Reports</i> , 15(5) Art. No. 404	1.983	36
9*	De Meerleer G, Khoo V, Escudier B., Joniau S, Bossi A., Ost P, Briganti A, Fontayne V, Van Vulpen M, Lumen N, Spahn M and Mareel M. Radiotherapy for renal-cell carcinoma. <i>Lancet Oncol.</i> 2014 Apr;15(4):e170-7.	36.481	122
10*	Joniau S, Tosco L, Briganti A, Vanden Broeck T, Gontero P, Karnes RJ, Spahn M , Van Poppel H. Results of surgery for high-risk prostate cancer. <i>Curr Opin Urol.</i> 2013 Jul;23(4):342-8	1.83	20
11*	Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M , Van Poppel H. Current role of surgery for high risk prostate cancer. <i>Arch Esp Urol.</i> 2013 Apr;66(3):259-73, 259-74	#	2
12*	Spahn M and Haeni K. Approach to prostate cancer in men older than 75 years : Active or passive? <i>Urologe A.</i> 2012 Oct;51(10):1368-74.	0.437	1
13*	Oderda M, Joniau S, Spahn M , Gontero P. Debulking surgery in the setting of very high-risk prostate cancer scenarios. <i>BJU Int.</i> 2012 Sep;110(6 Pt B):E192-8.	4.688	22
14	Spahn M and Krebs M. How should hormone therapy for castration-resistant prostate cancer be continued? <i>Urologe A.</i> 2012 Jan;51(1):15-9.	0.437	1
15	Van Baelen A, Mottet N, Spahn M , Briganti A, Gontero P, Joniau S. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. <i>Adv Urol.</i> 2012;2012:983058.	#	0
16	Riedmiller H and Spahn M . Surgery illustrated - surgical atlas: Open staghorn stone surgery. <i>BJU Int.</i> 2010 Sep;106(5):730-46.	4.688	0
17	Spahn M , Kocot A, Riedmiller H. Interventional and surgical treatment of urethral strictures. End-to-end anastomosis. <i>Urologe A.</i> 2010 Jun;49(6):720, 722-6.	0.437	0
18	Kocot A, Spahn M , Riedmiller H. Renal transplantation and urinary diversion. <i>Urologe A.</i> 2009 Dec;48(12):1452-5.	0.437	1

19	Wendt-Nordahl G, Evan AP, Spahn M , Knoll T. Calcium oxalate stone formation. New pathogenetic aspects of an old disease. Urologe A. 2008 May;47(5):538, 540-44.	0.437	4
20	Spahn M , Bader P, Westermann D, Echte D, Frohneberg D. Bladder carcinoma during pregnancy. Urol Int. 2005;74(2):153-9.	1.508	13
21	Trompeter M, Spahn M . Postoperative radiologic evaluation in urology. Part 2: Bladder, prostate, and testis. Radiologe. 2003 Aug;43(8):677-86	0.376	0
22	Trompeter M, Spahn M . Postoperative evaluation in urology. Part 1: Nephrolithiasis, renal tumors and diseases of the ureter. Radiologe. 2003 Jul;43(7):581-93	0.376	0
23	Fernández Arancibia MI, Martínez Portillo FJ, Musial A, Spahn M , Jünemann KP, Alken P. Diagnosis and therapeutic options for prolonged erection and priapism: up-date review. Arch Esp Urol. 2000 Dec;53(10):919-27.	#	0
24	Manning M, Spahn M , Jünemann KP. Vascular surgery, implant surgery and vacuum erectile aids. Review-overview-prospects of 3 therapy options in erectile dysfunction. Urologe A. 1998 Sep;37(5):509-15.	0.437	6

Liegt noch nicht vor

* Impactfaktoren gemäss Journal Citation report des Institute for Scientific Information (2018)

** Zitationen gemäss Institute for Scientific Information (13.01.2020)

IV BOOKCHAPTER

NUMBER: 10
First-/Seniorauthor: 7

Nr. Author / Titel / Year

1*	Frohneberg D., Spahn M. : „Renale und Retroperitoneale Raumforderungen“ in „Urologische Differenzialdiagnose“. J.W. Thüroff (Hrsg.), Thieme Verlag 2019.	B	
2*	Ambühl D, Thalmann G and Spahn M . Management of non-metastatic failure following local therapy (BCR, salvage RP, salvage PLND) in “Prostate Cancer” by Springer International, in press	B	
3*	Joniau,S, Briganti A, DeMeerleer G, Gontero P, Spahn M , Bruwaene and Karnes J. High risk prostate cancer. Oxford Textbook of Urological Surgery, Edited by F. Hamdy and E. Eardley, Oxford University press in press	B	
4*	Spahn M. Quality of Life with Orthotopic Bladder Substitution - Use of Validated Questionnaires –in: Keys to Successful Orthotopic Bladder Substitution. Edited by UE Studer, Springer-Verlag, in press	B	
5*	Thalmann G and Spahn M . Outcome of different forms of androgen deprivation therapy in prostate cancer. In: Advances in androgen deprivation with a GnRH antagonist in prostate cancer patients. Edited by T.M. de Reijke. Minerva Medica Verlag, in press.	B	-
6*	Thalmann G and Spahn M . Managing rising PSA, in naïve and post therapy patients. In: Prostate cancer: Diagnosis	B	-

	and Clinical management. Edited by Wheelan P, Tewari A and Graham J. Wiley-Blackwell Verlag, in press.		
7	Bossi A, Joniau S, Spahn M , Tombal B. How can high-risk non-metastatic disease be appropriately managed? In High-risk non-metastatic and metastatic prostate cancer. Edt.by Mottrie/Tombal/Van Poppel/De Meerleer; by Mirrors of Medicine, 2015, in press.	B	-
8	Kocot A, Spahn M , Riedmiller H: „Komplikationen bei der Harnröhrenchirurgie, allgemeine Aspekte, End-zu-End Anastomose, Mundschleimhaut“ in „Komplikationen in der Urologie.“ Anheuser/Steffens (Hrsg.), Thieme Verlag 2011	B	-
9	Spahn M , Bader P, Frohneberg D.: „Cock rings - das Dilemma nach dem Spass“ in „Kuriositäten aus dem urologischen Alltag“. C. Doehn, D. Jocham, Steinkopf Verlag 2009.	B	-
10	Frohneberg D., Spahn M. : „Renale und Retroperitoneale Raumforderungen“ in „Urologische Differenzialdiagnose“. J.W. Thüroff (Hrsg.), Thieme Verlag 2007.	B	-
11	Spahn M , Manning M, Jünemann KP.: „Intracavernosal Therapy“ in „Textbook of erectile dysfunction“. C.C. Carson, R. Kirby and I. Goldstein (Hrsg.), Isis Medica Media 1999.	B	-

V LETTER; EDITORIAL

Number: 15 (13 First-/Seniorauthor)
Cumulative IF: 209.76
Citation: 16

Nr.	Author / Titel / Year	*IF	*Citation
1*	Spahn M. Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Eur Urol. 2018 Jan;73(1):141-142.	17.581	0
2*	Spahn M. Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Eur Urol. 2018 Jan;73(1):141-142.	17.581	0
3*	Spahn M , Dal Pra A, Aebersold D, Tombal B. Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. Eur Urol. 2016 Feb 5. pii: S0302-2838(16)00168-8. doi: 10.1016/j.eururo.2016.01.049. [Epub ahead of print]	17.581	1
4*	Dal Pra A. and Spahn.M. Who is the patient who needs treatment intensification? Eur Urol 2016 Apr;69(4):e74-5	17.581	0
5*	Spahn M. More nomograms or better lymph node dissection what do we need in prostate cancer? BJU Int, 2015 Nov;116(5):676-7	4.688	0
6*	Gontero P, Spahn M , Marchioro G, Karnes JR, Briganti A, Frea B, Ricardi U, van Poppel H, Joniau S. Salvage radical prostatectomy in nonmetastatic castration-resistant prostate cancer patients who received previous radiotherapy: a feasibility study. Eur Urol. 2014 Jan;65(1):254-5.	17.581	0
7*	Joniou S, Tosco L, Van Poppel H, Spahn M. Minimally invasive vs open radical prostatectomy in high-risk prostate cancer: comparing apples and pears? BJU Int. 2013 Oct;112(6):711-2	4.688	1

8*	Spahn M. Is It Time To Change the Treatment Paradigm for Lymph Node-Positive Prostate Cancer? Eur Urol. 2013 Jul 2. pii: S0302-2838(13)00655-6	17.581	0
9	Spahn M and Joniau S. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol. 2012 Sep 5. S.0302-2838(12)	17.581	5
10*	Sooriakumaran P, Spahn M , Wiklund P. Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint. BJU Int. 2012 Aug;110(4):477-8.	4.688	6
11	Joniau S, Van den Bergh L, Peeters C, Haustermans K, Spahn M . Nodal staging in prostate cancer: still an unresolved issue. Eur Urol. 2012 Jun;61(6):1139-41.	17.581	2
12	Joniau S and Spahn M . Words of wisdom. Re: Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. Eur Urol. 2011 Nov;60(5):1121-2.	17.581	1
13	Spahn M. , Riedmiller H.: Re-Editorial comment to: Bladder Neck Closure and Continent Vesicostomy –Long Term Results and Comparison of Different Techniques. Urology, 2010, May; 75(5):1192.	2.3	0
14	Spahn M , Joniau S, Kneitz B, Gontero P, van Poppel H: Reply from Authors re: Defining and Treating High-risk Prostate Cancer: Can We Do Better? European Urology 2010, 58, 8-9.	17.581	0
15	Spahn M , Kneitz B, Gontero P, van Poppel H, Joniau S: Reply to Endre Zoltan Neulander and Zev Wejsman's Letter to the Editor re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. Eur Urol 2010;58:1-7. Eur Urol. 2010 May 20.	17.581	0

* Impactfaktoren gemäss Journal Citation report des Institute for Scientific Information (2018)

** Zitationen gemäss Institute for Scientific Information (13.01.2020)